Kobayashi Pharmaceutical Co., Ltd.
KBYPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $437,716,131 | $590,947,710 | $558,923,439 | $716,615,078 |
| - Cash | $50,873,000 | $71,536,000 | $96,233,000 | $95,024,000 |
| + Debt | $846,000 | $987,000 | $792,000 | $630,000 |
| Enterprise Value | $387,689,131 | $520,398,710 | $463,482,439 | $622,221,078 |
| Revenue | $165,600,000 | $173,455,000 | $166,258,000 | $155,252,000 |
| % Growth | -4.5% | 4.3% | 7.1% | – |
| Gross Profit | $87,603,000 | $96,376,000 | $92,331,000 | $88,774,000 |
| % Margin | 52.9% | 55.6% | 55.5% | 57.2% |
| EBITDA | $21,964,000 | $33,645,000 | $31,864,000 | $30,786,000 |
| % Margin | 13.3% | 19.4% | 19.2% | 19.8% |
| Net Income | $10,067,000 | $20,338,000 | $20,022,000 | $19,715,000 |
| % Margin | 6.1% | 11.7% | 12% | 12.7% |
| EPS Diluted | 135.42 | 268.16 | 259.59 | 252.36 |
| % Growth | -49.5% | 3.3% | 2.9% | – |
| Operating Cash Flow | $11,246,000 | $18,360,000 | $31,914,000 | $22,419,000 |
| Capital Expenditures | -$26,629,000 | -$13,569,000 | -$16,229,000 | -$4,185,000 |
| Free Cash Flow | -$15,383,000 | $4,791,000 | $15,685,000 | $18,234,000 |